Pentadecapeptide BPC 157 Anti‐Ulcer Effect After Stomach Perforation also Opposed the Intracranial Hypertension (Superior Sagittal Sinus), Portal and Caval Hypertension and Aortal Hypotension

Abstract

We report that rat stomach perforation (surgery with 5‐mm diameter metal needle on the ventral side in the prepyloric area) induced a defect that would not heal. Also, stomach perforation rapidly induced the intracranial hypertension (superior sagittal sinus), portal and caval hypertension and aortal hypotension. Stable gastric pentadecapeptide BPC 157 largely attenuated or eliminated these pressure disturbances. Finally, BPC 157 completely healed stomach defect. Previously, BPC 157 largely attenuated or even eliminated the consequences of Budd‐Chiari syndrome in rats, in particular, portal and caval hypertension and aortal hypotension, and then, huge thrombosis in both veins and arteries, and multiple organ dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal lesions. These beneficial effects may relieve a Virchow's triad situation that may be commonly presented as well as counteracted (i.e.,duodenal venous congestion lesions (World J Gastroenterol 2018), perforated cecum (World J Gastroenterol 2018), bile duct ligation induced liver cirrhosis and portal hypertension (Eur J Pharmacol 2109), Pringle maneuver, ischemia, reperfusion (World J Hepatol 2020), and suprahepatic occlusion of the inferior caval vein (Budd‐Chiari‐syndrome) (World J Gastrointest Pathophysiol 2020)). Likewise, given in reperfusion, after clamping of the common carotid arteries, BPC 157 counteracted stroke (i.e., both early and delayed neural hippocampal damage, achieving also full functional recovery) (Brain Behav 2020).MethodsTherapy (BPC 157 (10 µg or 10 ng/kg) or saline (5 ml/kg)) was given intragatrically, at 1 min after stomach perforation. At 5 min after stomach perforation, as described before (World J Hepatol 2020), recordings were made in deeply anesthetized rats. Briefly, a cannula (BD Neoflon™ Cannula) was connected to a pressure transducer (78534C MONITOR/ TERMINAL; Hewlett Packard, USA) inserted into the superior sagittal sinus, and portal vein, and inferior vena cava, and abdominal aorta at the level of the bifurcation. We used five minutes recording. For superior sagittal sinus pressure recording, we made a single burr hole in the rostral part of the sagittal suture, above the superior sagittal sinus, and cannulated superior sagittal sinus anterior part by Braun intravenous cannulas, and then, in laparatomized rats, we recorded portal vein, inferior vena cava and abdominal aorta pressure.ResultsWithout therapy, the severely increased intracranial hypertension (10±2 mmHg in superior sagittal sinus), portal (33±4 mmHg) and caval (28±3 mmHg) hypertension and aortal hypotension (59±3 mmHg) occurred rapidly. Both BPC 157 regimens markedly counteracted intracranial hypertension (‐6±2 mmHg in superior sagittal sinus), portal (6±2 mmHg) and caval (5±2 mmHg) hypertension and aortal hypotension (81±3 mmHg) (i.e., 10 ng).ConclusionBPC 157 anti‐ulcer effect also opposed the intracranial hypertension (superior sagittal sinus), portal and caval hypertension and aortal hypotension.